Ramalingam Preetha, Masand Ramya P, Euscher Elizabeth D, Malpica Anais
University of Texas MD Anderson Cancer Center, Houston, Texas.
Int J Gynecol Pathol. 2016 Sep;35(5):410-8. doi: 10.1097/PGP.0000000000000248.
Undifferentiated carcinoma of the endometrium (UCAe) is an aggressive, underrecognized high-grade carcinoma that can occur either in pure form or in conjunction with low-grade endometrioid adenocarcinoma (i.e. dedifferentiated carcinoma). The typical solid growth pattern of UCAe can create a diagnostic dilemma as it is frequently misinterpreted as the solid component of an endometrial carcinoma or as a sarcoma. In addition, the high nuclear:cytoplasmic ratio, high mitotic index, and geographic necrosis are reminiscent of basal-like carcinoma of breast (BLCB). This study was undertaken to determine the role of a selected group of immunomarkers in the distinction of UCAe from other endometrial carcinomas, and assess the expression of DNA mismatch repair proteins, and surrogate BLCB immunomarkers in this type of tumor. Cases of UCAe were stained with antibodies against keratin cocktail, CK8/18, PAX-8, and estrogen receptor: 35 cases; progesterone receptor and Her-2/neu: 33 cases; CD44, e-cadherin, p16, and p53: 32 cases; and CK5/6, EGFR, and c-Kit: 18 cases. In addition, mismatch repair protein markers MLH1, MSH2, MSH6, and PMS2 were performed in 34 cases. We found that PAX-8 expression was lost in most cases (83%). In addition, estrogen and progesterone receptors were negative in 83% and 82% of cases, respectively. Seventy-seven percent of cases were positive for keratin cocktail and keratin 8/18, whereas only 11% of cases were positive for keratin 5/6. p16 was diffusely positive in 34% of cases, whereas p53 was expressed in >75% of the tumor cells in 31% of cases. MLH1 and PMS2 were concurrently lost in 50% of cases, whereas MSH2 and MSH6 were lost in 1 case (3%). E-cadherin and CD44 were completely lost in 50% of cases, whereas Her-2/neu was negative in all cases. EGFR was negative in 67% of cases, whereas 22% of cases showed diffuse membranous staining for this marker. UCAe is a high-grade carcinoma of Müllerian origin which tends to be negative for PAX-8. The loss of this marker appears to be a more reliable discriminator than the loss of keratin expression in the differential diagnosis with endometrioid carcinoma or serous carcinoma. UCAe tends to be diffusely positive for p53, but patchy positive for p16. Although UCAe appears to share not only some histologic features with BLCB, but also some of its immunohistochemical features (loss of estrogen receptor, progesterone receptor, and Her-2/neu, a tendency to loose e-cadherin and to express CD44), UCAe appears not to be related to BLCB because it usually lacks the expression EGFR, CK5/6, and c-Kit.
子宫内膜未分化癌(UCAe)是一种侵袭性强、认识不足的高级别癌,可呈纯形式出现,也可与低级别子宫内膜样腺癌同时出现(即去分化癌)。UCAe典型的实性生长模式会造成诊断难题,因为它常被误诊为子宫内膜癌的实性成分或肉瘤。此外,高核质比、高有丝分裂指数和地图状坏死让人联想到乳腺基底样癌(BLCB)。本研究旨在确定一组选定免疫标志物在鉴别UCAe与其他子宫内膜癌中的作用,并评估此类肿瘤中DNA错配修复蛋白及替代BLCB免疫标志物的表达。用抗细胞角蛋白混合物、CK8/18、PAX-8和雌激素受体的抗体对UCAe病例进行染色:35例;用抗孕激素受体和Her-2/neu的抗体染色:33例;用抗CD44、E-钙黏蛋白、p16和p53的抗体染色:32例;用抗CK5/6、表皮生长因子受体(EGFR)和原癌基因c-Kit的抗体染色:18例。此外,对34例进行错配修复蛋白标志物MLH1、MSH2、MSH6和PMS2检测。我们发现,大多数病例(83%)PAX-8表达缺失。此外,83%和82%的病例雌激素和孕激素受体分别为阴性。77%的病例细胞角蛋白混合物和角蛋白8/18呈阳性,而只有11%的病例角蛋白5/6呈阳性。34%的病例p16弥漫性阳性,而31%的病例中>75%的肿瘤细胞表达p53。50%的病例MLH1和PMS2同时缺失,而1例(3%)病例MSH2和MSH6缺失。50%的病例E-钙黏蛋白和CD44完全缺失,而所有病例Her-2/neu均为阴性。67%的病例EGFR为阴性,而22%的病例该标志物呈弥漫性膜染色。UCAe是一种苗勒氏源性高级别癌,PAX-8往往为阴性。在与子宫内膜样癌或浆液性癌的鉴别诊断中,该标志物的缺失似乎比角蛋白表达缺失更可靠。UCAe往往p53弥漫性阳性,但p16呈局灶性阳性。尽管UCAe似乎不仅与BLCB有一些组织学特征相同,而且在免疫组化特征方面也有一些相同之处(雌激素受体、孕激素受体和Her-2/neu缺失,E-钙黏蛋白有丢失倾向且表达CD44),但UCAe似乎与BLCB无关,因为它通常缺乏EGFR、CK5/6和c-Kit的表达。